Joe H Chang1, John H Shin2, Yoshiya J Yamada3, Addisu Mesfin4, Michael G Fehlings5, Laurence D Rhines6, Arjun Sahgal1. 1. Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 2. Department of Neurosurgery, Massachusetts General Hospital, Harvard University, Boston, MA. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York. 4. Department of Orthopaedic Surgery, University of Rochester, Rochester, NY. 5. Department of Neurosurgery and Spinal Program, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 6. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
STUDY DESIGN: Systematic literature review. OBJECTIVES: To summarize the risks of 3 key complications of stereotactic body radiotherapy (SBRT) for spinal metastases, that is, radiation myelopathy (RM), vertebral compression fracture (VCF), and epidural disease progression, and to discuss strategies for minimizing them. SUMMARY OF BACKGROUND DATA: RM, VCF and epidural disease progression are now recognized as important risks following SBRT for spine metastases. It is unclear at this stage exactly how large these risks are and what strategies can be employed to minimize these risks. METHODS: A systematic review of the literature using MEDLINE and a review of the bibliographies of reviewed articles on SBRT for spinal metastases were conducted. RESULTS: The initial literature search revealed a total of 376 articles, of which 38 were pertinent to the study objectives. The risk of RM following SBRT was found to be dependent on the maximum dose to the spinal cord and estimated to be ≤5% if the recommended published thecal sac dose constraints are adhered to. The crude risk of VCF was 13.7% (range: 0.7%-40.5%), and, on average, 45% were surgically salvaged. It has been shown that the risk of VCF is dependent on several anatomic and tumor-related factors including the SBRT dose per fraction. The crude risk of local failure at 1 year was 21.4% (range: 12%-27%) of which 67% (range: 38%-96%) occurred within the epidural space. The grade of epidural disease has been shown to be associated with the risk of local failure. CONCLUSION: The risk of RM after spinal SBRT is low in particular if recommended dose metrics are adhered to. There is a significant risk of both VCF and epidural disease progression after spinal SBRT. These risks can potentially be minimized by identifying the risk factors for these complications, and performing careful radiotherapy and surgical planning. LEVEL OF EVIDENCE: 2.
STUDY DESIGN: Systematic literature review. OBJECTIVES: To summarize the risks of 3 key complications of stereotactic body radiotherapy (SBRT) for spinal metastases, that is, radiation myelopathy (RM), vertebral compression fracture (VCF), and epidural disease progression, and to discuss strategies for minimizing them. SUMMARY OF BACKGROUND DATA: RM, VCF and epidural disease progression are now recognized as important risks following SBRT for spine metastases. It is unclear at this stage exactly how large these risks are and what strategies can be employed to minimize these risks. METHODS: A systematic review of the literature using MEDLINE and a review of the bibliographies of reviewed articles on SBRT for spinal metastases were conducted. RESULTS: The initial literature search revealed a total of 376 articles, of which 38 were pertinent to the study objectives. The risk of RM following SBRT was found to be dependent on the maximum dose to the spinal cord and estimated to be ≤5% if the recommended published thecal sac dose constraints are adhered to. The crude risk of VCF was 13.7% (range: 0.7%-40.5%), and, on average, 45% were surgically salvaged. It has been shown that the risk of VCF is dependent on several anatomic and tumor-related factors including the SBRT dose per fraction. The crude risk of local failure at 1 year was 21.4% (range: 12%-27%) of which 67% (range: 38%-96%) occurred within the epidural space. The grade of epidural disease has been shown to be associated with the risk of local failure. CONCLUSION: The risk of RM after spinal SBRT is low in particular if recommended dose metrics are adhered to. There is a significant risk of both VCF and epidural disease progression after spinal SBRT. These risks can potentially be minimized by identifying the risk factors for these complications, and performing careful radiotherapy and surgical planning. LEVEL OF EVIDENCE: 2.
Authors: Amit K Garg; Xin-Shelley Wang; Almon S Shiu; Pamela Allen; James Yang; Mary Frances McAleer; Syed Azeem; Laurence D Rhines; Eric L Chang Journal: Cancer Date: 2011-02-11 Impact factor: 6.860
Authors: Kamran A Ahmed; Michael C Stauder; Robert C Miller; Heather J Bauer; Peter S Rose; Kenneth R Olivier; Paul D Brown; Debra H Brinkmann; Nadia N Laack Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-11 Impact factor: 7.038
Authors: Nicholas S Boehling; David R Grosshans; Pamela K Allen; Mary F McAleer; Allen W Burton; Syed Azeem; Laurence D Rhines; Eric L Chang Journal: J Neurosurg Spine Date: 2012-01-06
Authors: Isabelle Thibault; Mikki Campbell; Chia-Lin Tseng; Eshetu G Atenafu; Daniel Letourneau; Eugene Yu; B C John Cho; Young K Lee; Michael G Fehlings; Arjun Sahgal Journal: Int J Radiat Oncol Biol Phys Date: 2015-10-01 Impact factor: 7.038
Authors: Giuseppe Di Perna; Fabio Cofano; Cristina Mantovani; Serena Badellino; Nicola Marengo; Marco Ajello; Ludovico Maria Comite; Giuseppe Palmieri; Fulvio Tartara; Francesco Zenga; Umberto Ricardi; Diego Garbossa Journal: J Bone Oncol Date: 2020-09-26 Impact factor: 4.072
Authors: Katie L Spencer; Joanne M van der Velden; Erin Wong; Enrica Seravalli; Arjun Sahgal; Edward Chow; Jorrit-Jan Verlaan; Helena M Verkooijen; Yvette M van der Linden Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: Yurday Ozdemir; Nese Torun; Ozan Cem Guler; Berna Akkus Yildirim; Ali A Besen; Aylin Gunesli Yetisken; H Cem Onal; Erkan Topkan Journal: J Bone Oncol Date: 2019-01-24 Impact factor: 4.072
Authors: Poonam Yadav; Hima B Musunuru; Jacob S Witt; Michael Bassetti; John Bayouth; Andrew M Baschnagel Journal: Radiol Oncol Date: 2019-09-24 Impact factor: 2.991
Authors: Dirk Rades; Olfred Hansen; Lars Henrik Jensen; Liesa Dziggel; Christian Staackmann; Claudia Doemer; Jon Cacicedo; Antonio J Conde-Moreno; Barbara Segedin; Raquel Ciervide-Jurio; Carmen Rubio-Rodriguez; Luis A Perez-Romasanta; Ana Alvarez-Gracia; Kristopher Dennis; Carlos Ferrer-Albiach; Arturo Navarro-Martin; Fernando Lopez-Campos; Natalia Jankarashvili; Stefan Janssen; Denise Olbrich; Niels Henrik Holländer Journal: BMC Cancer Date: 2019-11-29 Impact factor: 4.430